Anti-Follistatin 288 [29/9]

Tool Details

*FOR RESEARCH USE ONLY

• Name: Anti-Follistatin 288 [29/9]
• Alternate name: Follistatin, FS, FST, Active-binding protein
• Clone: 3.22222222222
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Molecular weight: 37 kDa
• Strain: Balb/c
• Reactivity: Human
• Host: Mouse
• Application: ELISA
• Description: Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS288 is the main cell-surface form and binds to surface heparin sulphate proteoglycans. 29/9 is a clone raised against recombinant Fst 288, and is used in combination, commonly as the capture, with antibody 17/2 in a two site ELISA for the detection of Follistatin.
• Immunogen: Raised to human Follistatin (Fst) 288 and recognizes both human Fst 288 and 315
• Isotype: IgG1
• Myeloma used: Sp2/0-Ag14
• Recommended controls: Testis or Ovary

Target Details

• Target: Follistation 288
• Molecular weight: 37 kDa
• Tissue cell line specificity: Testis or Ovary
• Target background: Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS288 is the main cell-surface form and binds to surface heparin sulphate proteoglycans. 29/9 is a clone raised against recombinant Fst 288, and is used in combination, commonly as the capture, with antibody 17/2 in a two site ELISA for the detection of Follistatin.

Applications

• Application: ELISA

Handling

• Format: Liquid
• Unit size: 100 ug
• Shipping conditions: Shipping at 4° C

References

• Hughes et al. 2003. Eur J Gastroenterol Hepatol. 15(2):127-31. PMID: 12560755.
• Activin A and follistatin in acute liver failure.
• Yuen et al. 2002. Scand J Gastroenterol. 37(2):233-8. PMID: 11843063.
• Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis.
• Menon et al. 2000. BJOG. 107(9):1069-74. PMID: 11002947.
• Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma.
• McPherson et al. 1999. Endocrinology. 140(11):5303-9. PMID: 10537161.
• Expression of activin A and follistatin core proteins by human prostate tumor cell lines.
• Cuckle et al. 1999. Prenat Diagn. 19(6):513-6. PMID: 10416964.
• Maternal serum activin A and follistatin levels in pregnancies with Down syndrome.
• Fowler et al. 1998. Hum Reprod. 13(12):3530-6. PMID: 9886545.
• Anderson et al. 1998. Hum Reprod. 13(12):3319-25. PMID: 9886507.
• Follistatin and activin A production by the male reproductive tract.
• A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and follistatin during pregnancy.
• Riley et al. 1998. Hum Reprod. 13(9):2624-8. PMID: 9806296.
• Follistatin and activin A in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy.
• Evans et al. 1998. J Endocrinol. 156(2):275-82. PMID: 9518873.
• Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin.
• Petraglia et al. 1997. J Clin Endocrinol Metab. 82(9):2991-5. PMID: 9284732.
• Changes of dimeric inhibin B levels in maternal serum throughout healthy gestation and in women with gestational diseases.